572 related articles for article (PubMed ID: 34544279)
1. SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.
Liu Y; Qin C; Rao Y; Ngo C; Feng JJ; Zhao J; Zhang S; Wang TY; Carriere J; Savas AC; Zarinfar M; Rice S; Yang H; Yuan W; Camarero JA; Yu J; Chen XS; Zhang C; Feng P
mBio; 2021 Oct; 12(5):e0233521. PubMed ID: 34544279
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules.
Zheng Y; Deng J; Han L; Zhuang MW; Xu Y; Zhang J; Nan ML; Xiao Y; Zhan P; Liu X; Gao C; Wang PH
Signal Transduct Target Ther; 2022 Jan; 7(1):22. PubMed ID: 35075101
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the RLR signaling pathway by SARS-CoV-2 ORF7b is mediated by MAVS and abrogated by ORF7b-homologous interfering peptide.
Xiao X; Fu Y; You W; Huang C; Zeng F; Gu X; Sun X; Li J; Zhang Q; Du W; Cheng G; Liu Z; Liu L
J Virol; 2024 May; 98(5):e0157323. PubMed ID: 38572974
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog.
Chen J; Li Z; Guo J; Xu S; Zhou J; Chen Q; Tong X; Wang D; Peng G; Fang L; Xiao S
J Virol; 2022 Apr; 96(8):e0003722. PubMed ID: 35389264
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of RIG-I like receptors in SARS-CoV-2 infection.
Yang DM; Geng TT; Harrison AG; Wang PH
Mil Med Res; 2021 Sep; 8(1):49. PubMed ID: 34488908
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Nsp5 Activates NF-κB Pathway by Upregulating SUMOylation of MAVS.
Li W; Qiao J; You Q; Zong S; Peng Q; Liu Y; Hu S; Liu W; Li S; Shu X; Sun B
Front Immunol; 2021; 12():750969. PubMed ID: 34858407
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling.
Zheng Y; Zhuang MW; Han L; Zhang J; Nan ML; Zhan P; Kang D; Liu X; Gao C; Wang PH
Signal Transduct Target Ther; 2020 Dec; 5(1):299. PubMed ID: 33372174
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO.
Wu J; Shi Y; Pan X; Wu S; Hou R; Zhang Y; Zhong T; Tang H; Du W; Wang L; Wo J; Mu J; Qiu Y; Yang K; Zhang LK; Ye BC; Qi N
Cell Rep; 2021 Feb; 34(7):108761. PubMed ID: 33567255
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
12. Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner.
Ran XH; Zhu JW; Chen YY; Ni RZ; Mu D
Front Immunol; 2022; 13():947272. PubMed ID: 36032116
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy.
Li X; Hou P; Ma W; Wang X; Wang H; Yu Z; Chang H; Wang T; Jin S; Wang X; Wang W; Zhao Y; Zhao Y; Xu C; Ma X; Gao Y; He H
Cell Mol Immunol; 2022 Jan; 19(1):67-78. PubMed ID: 34845370
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation.
Wang W; Zhou Z; Xiao X; Tian Z; Dong X; Wang C; Li L; Ren L; Lei X; Xiang Z; Wang J
Cell Mol Immunol; 2021 Apr; 18(4):945-953. PubMed ID: 33637958
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of RIG-I and MAVS by MARCH5 mitochondria ubiquitin ligase in innate immunity.
Park YJ; Oanh NTK; Heo J; Kim SG; Lee HS; Lee H; Lee JH; Kang HC; Lim W; Yoo YS; Cho H
Cell Signal; 2020 Mar; 67():109520. PubMed ID: 31881323
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor Pathways to Inhibit the Induction of Interferon Response.
Oh SJ; Shin OS
Cells; 2021 Mar; 10(3):. PubMed ID: 33801464
[TBL] [Abstract][Full Text] [Related]
17. RIG-I-Like Receptor-Mediated Recognition of Viral Genomic RNA of Severe Acute Respiratory Syndrome Coronavirus-2 and Viral Escape From the Host Innate Immune Responses.
Kouwaki T; Nishimura T; Wang G; Oshiumi H
Front Immunol; 2021; 12():700926. PubMed ID: 34249006
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3.
Fung SY; Siu KL; Lin H; Yeung ML; Jin DY
Int J Biol Sci; 2021; 17(6):1547-1554. PubMed ID: 33907518
[TBL] [Abstract][Full Text] [Related]
19. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells.
Yamada T; Sato S; Sotoyama Y; Orba Y; Sawa H; Yamauchi H; Sasaki M; Takaoka A
Nat Immunol; 2021 Jul; 22(7):820-828. PubMed ID: 33976430
[TBL] [Abstract][Full Text] [Related]
20. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome.
Shi CS; Qi HY; Boularan C; Huang NN; Abu-Asab M; Shelhamer JH; Kehrl JH
J Immunol; 2014 Sep; 193(6):3080-9. PubMed ID: 25135833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
